Preclinical characterization of the Toll-like receptor 7/8 antagonist MHV370 for lupus therapy.

Saved in:
Bibliographic Details
Title: Preclinical characterization of the Toll-like receptor 7/8 antagonist MHV370 for lupus therapy.
Authors: Hawtin S; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland., André C; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland., Collignon-Zipfel G; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland., Appenzeller S; Department of Orthopedics, Rheumatology, and Traumatology, School of Medical Science, University of Campinas (UNICAMP), Campinas, 13083-887 São Paulo, Brazil., Bannert B; Department of Rheumatology, University Hospital Basel and University of Basel, 4031 Basel, Switzerland., Baumgartner L; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland., Beck D; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland., Betschart C; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland., Boulay T; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland., Brunner HI; Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA., Ceci M; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland., Deane J; Novartis Institutes for BioMedical Research, Novartis Pharma AG, La Jolla, CA 92121, USA., Feifel R; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland., Ferrero E; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland., Kyburz D; Department of Rheumatology, University Hospital Basel and University of Basel, 4031 Basel, Switzerland., Lafossas F; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland., Loetscher P; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland., Merz-Stoeckle C; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland., Michellys P; Novartis Institutes for BioMedical Research, Novartis Pharma AG, La Jolla, CA 92121, USA., Nuesslein-Hildesheim B; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland., Raulf F; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland., Rush JS; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland., Ruzzante G; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland., Stein T; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland., Zaharevitz S; Novartis Institutes for BioMedical Research, Novartis Pharma AG, La Jolla, CA 92121, USA., Wieczorek G; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland., Siegel R; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland., Gergely P; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland., Shisha T; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland., Junt T; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland. Electronic address: tobias.junt@novartis.com.
Source: Cell reports. Medicine [Cell Rep Med] 2023 May 16; Vol. 4 (5), pp. 101036.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Cell Press Country of Publication: United States NLM ID: 101766894 Publication Model: Print Cited Medium: Internet ISSN: 2666-3791 (Electronic) Linking ISSN: 26663791 NLM ISO Abbreviation: Cell Rep Med Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2666-3791
DOI:10.1016/j.xcrm.2023.101036